Compare Stocks → AI “wealth window” is closing soon! (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison TSE:APSCVE:IGXNASDAQ:PDPNASDAQ:PMN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPSAptose BiosciencesC$1.75C$2.20C$1.71▼C$11.40C$27.49M1.448,872 shs10,978 shsIGXIntelGenx TechnologiesC$0.58+1.8%C$0.58C$0.17▼C$0.85C$87.32MN/A56,279 shs11,848 shsPDPInvesco Dorsey Wright Momentum ETF$92.04-0.8%$95.39$72.68▼$99.60$1.19B1.0226,719 shs10,918 shsPMNProMIS Neurosciences$1.97+5.9%$2.04$0.95▼$8.95$35.27M0.6740,588 shs13,493 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPSAptose Biosciences0.00%-7.89%-12.94%-40.27%+157.35%IGXIntelGenx Technologies0.00%0.00%0.00%0.00%0.00%PDPInvesco Dorsey Wright Momentum ETF-0.80%-4.63%-4.69%+6.48%+20.74%PMNProMIS Neurosciences+5.91%-16.17%+0.51%-10.86%-62.12%AI “wealth window” is closing soon! (Ad)Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.I put together this personal video [HERE]…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPSAptose BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AIGXIntelGenx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/APDPInvesco Dorsey Wright Momentum ETFN/AN/AN/AN/AN/AN/AN/AN/APMNProMIS Neurosciences2.7897 of 5 stars3.54.00.00.03.11.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPSAptose BiosciencesN/AN/AN/AN/AIGXIntelGenx TechnologiesN/AN/AN/AN/APDPInvesco Dorsey Wright Momentum ETF0.00N/A$95.724.00% UpsidePMNProMIS Neurosciences3.00Buy$8.00306.09% UpsideCurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPSAptose BiosciencesN/AN/AC$1.09 per share1.60C$1.03 per shareN/AIGXIntelGenx TechnologiesC$1.75M49.95C$0.08 per share7.16C$0.05 per share12.89PDPInvesco Dorsey Wright Momentum ETFN/AN/AN/AN/AN/AN/APMNProMIS Neurosciences$10K3,735.32N/AN/A$0.20 per share9.85Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPSAptose Biosciences-C$51.21M-C$10.49N/A∞N/AN/A-225.00%-102.23%5/13/2024 (Estimated)IGXIntelGenx TechnologiesN/A-C$0.08N/A∞N/AN/AN/AN/AN/APDPInvesco Dorsey Wright Momentum ETFN/AN/A25.46∞N/AN/AN/AN/AN/APMNProMIS Neurosciences-$13.21M-$1.13N/AN/AN/AN/AN/A-141.23%5/20/2024 (Estimated)Latest APS, IGX, PMN, and PDP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023PMNProMIS NeurosciencesN/A-$0.09-$0.09-$0.09N/AN/A3/26/2024Q4 2023APSAptose Biosciences-C$1.98-C$1.96+C$0.02-C$1.96N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPSAptose BiosciencesN/AN/AN/AN/AN/AIGXIntelGenx TechnologiesN/AN/AN/AN/AN/APDPInvesco Dorsey Wright Momentum ETF$0.250.27%N/AN/AN/APMNProMIS NeurosciencesN/AN/AN/AN/AN/ALatest APS, IGX, PMN, and PDP DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/15/2024PDPInvesco Dorsey Wright Momentum ETFQuarterly$0.02753/18/20243/19/20243/22/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPSAptose Biosciences14.270.785.41IGXIntelGenx Technologies164.622.772.69PDPInvesco Dorsey Wright Momentum ETFN/AN/AN/APMNProMIS NeurosciencesN/A1.461.46OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPSAptose Biosciences9.80%IGXIntelGenx TechnologiesN/APDPInvesco Dorsey Wright Momentum ETFN/APMNProMIS Neurosciences50.13%Insider OwnershipCompanyInsider OwnershipAPSAptose Biosciences20.20%IGXIntelGenx TechnologiesN/APDPInvesco Dorsey Wright Momentum ETFN/APMNProMIS Neurosciences10.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPSAptose Biosciences3115.71 millionN/ANot OptionableIGXIntelGenx Technologies48150.55 millionN/ANot OptionablePDPInvesco Dorsey Wright Momentum ETFN/A12.91 millionN/AOptionablePMNProMIS Neurosciences618.96 million17.01 millionNot OptionableAPS, IGX, PMN, and PDP HeadlinesSourceHeadlineProMIS Neurosciences (PMN) Price Target Increased by 9.38% to 8.93msn.com - April 17 at 9:02 AMProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALSglobenewswire.com - April 9 at 7:00 AMProMIS Neurosciences to Present in Upcoming Investor Conferences in Aprilglobenewswire.com - April 4 at 7:00 AMProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlightsglobenewswire.com - April 1 at 4:15 PMProMIS Neurosciences Strengthens Global Intellectual Property Portfolioglobenewswire.com - March 11 at 7:00 AMProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conferenceglobenewswire.com - February 22 at 7:00 AMResearchers discover a promising compound to treat neuropathic paininterestingengineering.com - February 4 at 12:20 AMProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccinefinance.yahoo.com - January 22 at 8:48 AMProMIS Neurosciences Inc.: ProMIS Neurosciences, Inc. Announces Leadership Transitionfinanznachrichten.de - January 3 at 9:13 AMBTIG Reaffirms Their Buy Rating on ProMIS Neurosciences (PMN)markets.businessinsider.com - January 3 at 9:13 AMProMIS Neurosciences Appoints Neil Warma As Interim Chief Executive Officermarkets.businessinsider.com - January 3 at 9:13 AMProMIS Neurosciences, Inc. Announces Leadership Transitionfinance.yahoo.com - January 3 at 9:13 AMProMIS Neurosciences GAAP EPS of -$0.19 beats by $0.14msn.com - November 14 at 7:10 PMProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - September 6 at 3:28 PMProMIS Neurosciences Inc. [PMN] Investment Appeal on the Riseknoxdaily.com - August 23 at 4:58 PMProMIS Neurosciences scales 31% on $20.4M private placementmsn.com - August 22 at 7:40 AMProMIS Neurosciences Announces $20.4 Million Private Placement Financingfinance.yahoo.com - August 21 at 4:38 PMProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlightsfinance.yahoo.com - May 15 at 6:49 PMClosing Bell: Promis Neurosciences Inc down on Friday (PMN)theglobeandmail.com - May 6 at 8:15 AMClosing Bell: Promis Neurosciences Inc up on Thursday (PMN)theglobeandmail.com - April 27 at 10:10 PMData Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Diseasefinance.yahoo.com - April 25 at 5:52 PMProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meetingfinance.yahoo.com - April 24 at 8:50 AMClosing Bell: Promis Neurosciences Inc up on Tuesday (PMN)theglobeandmail.com - April 19 at 1:59 AMClosing Bell: Promis Neurosciences Inc down on Monday (PMN)theglobeandmail.com - April 18 at 3:38 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideConsumer Sentiment Highest Since 2021, 3 Stocks Leading the WayApril 1, 2024 9:25 AMView Consumer Sentiment Highest Since 2021, 3 Stocks Leading the WayAll Headlines Company DescriptionsAptose BiosciencesTSE:APSAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.IntelGenx TechnologiesCVE:IGXIntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid addition; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, and INT0053/2020. The company has licensing, development, and supply agreement with Tilray, Inc. and Gensco Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.Invesco Dorsey Wright Momentum ETFNASDAQ:PDPPowerShares DWA Technical Leaders Portfolio (the Fund) is based on the Dorsey Wright Technical Leaders Index (the Index). The Fund seeks investment results that generally correspond to the price and yield of the Index. The Fund will normally invest at least 90% of its total assets in securities that consists of the Index and American Depositary Receipts (ADRs) based on the securities in the Index. The Index includes approximately 100 the United States-listed companies. Invesco PowerShares Capital Management LLC acts as the Fund's investment adviser.ProMIS NeurosciencesNASDAQ:PMNProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.